Lepagnol-Bestel A, Haziza S, Viard J, Salin P, Duchon A, Herault Y
Life (Basel). 2025; 15(2).
PMID: 40003558
PMC: 11856406.
DOI: 10.3390/life15020149.
Malueg M, Moo K, Arnett A, Edwards T, Ruskin S, Lambert K
Immunohorizons. 2025; 9(1).
PMID: 39846842
PMC: 11841973.
DOI: 10.1093/immhor/vlae005.
Brown M, Sciascia E, Ning K, Adam W, Veraksa A
G3 (Bethesda). 2024; 14(11).
PMID: 39271109
PMC: 11540318.
DOI: 10.1093/g3journal/jkae219.
Kadyan P, Singh L
Pharmacol Rep. 2024; 76(4):665-678.
PMID: 38758470
DOI: 10.1007/s43440-024-00602-8.
Haut F, Argyrousi E, Arancio O
Int J Mol Sci. 2024; 25(1).
PMID: 38203429
PMC: 10779219.
DOI: 10.3390/ijms25010259.
GR/Ahi1 regulates WDR68-DYRK1A binding and mediates cognitive impairment in prenatally stressed offspring.
Wei B, Shi H, Yu X, Shi Y, Zeng H, Zhao Y
Cell Mol Life Sci. 2024; 81(1):20.
PMID: 38195774
PMC: 11073104.
DOI: 10.1007/s00018-023-05075-1.
Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A.
Manubens-Gil L, Pons-Espinal M, Gener T, Ballesteros-Yanez I, Martinez de Lagran M, Dierssen M
Cereb Cortex. 2023; 34(1).
PMID: 37997361
PMC: 10793573.
DOI: 10.1093/cercor/bhad431.
Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model.
Hawley L, Stringer M, Deal A, Folz A, Goodlett C, Roper R
Neurobiol Dis. 2023; 190:106359.
PMID: 37992782
PMC: 10843801.
DOI: 10.1016/j.nbd.2023.106359.
New insights into the roles for DYRK family in mammalian development and congenital diseases.
Yoshida S, Yoshida K
Genes Dis. 2023; 10(3):758-770.
PMID: 37396550
PMC: 10308075.
DOI: 10.1016/j.gendis.2021.12.004.
Craniofacial dysmorphology in Down syndrome is caused by increased dosage of Dyrk1a and at least three other genes.
Redhead Y, Gibbins D, Lana-Elola E, Watson-Scales S, Dobson L, Krause M
Development. 2023; 150(8).
PMID: 37102702
PMC: 10163349.
DOI: 10.1242/dev.201077.
DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
Zhu B, Parsons T, Foley C, Shaw Y, Dunckley T, Hulme C
Sci Rep. 2022; 12(1):15847.
PMID: 36151233
PMC: 9508268.
DOI: 10.1038/s41598-022-19967-y.
DYRK1a Inhibitor Mediated Rescue of Models of Alzheimer's Disease-Down Syndrome Phenotypes.
Zhu B, Parsons T, Stensen W, Mjoen Svendsen J, Fugelli A, Hodge J
Front Pharmacol. 2022; 13:881385.
PMID: 35928283
PMC: 9345315.
DOI: 10.3389/fphar.2022.881385.
Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.
Viard J, Loe-Mie Y, Daudin R, Khelfaoui M, Plancon C, Boland A
Life Sci Alliance. 2022; 5(12).
PMID: 35914814
PMC: 9348576.
DOI: 10.26508/lsa.202101205.
The accumulation of copper in the brain of Down syndrome promotes oxidative stress: possible mechanism underlying cognitive impairment.
Ishihara K
J Clin Biochem Nutr. 2022; 71(1):16-21.
PMID: 35903608
PMC: 9309086.
DOI: 10.3164/jcbn.21-155.
Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley L, Prochaska F, Stringer M, Goodlett C, Roper R
Pharmacol Biochem Behav. 2022; 217:173404.
PMID: 35576991
PMC: 9516663.
DOI: 10.1016/j.pbb.2022.173404.
Effects of aneuploidy on cell behaviour and function.
Li R, Zhu J
Nat Rev Mol Cell Biol. 2022; 23(4):250-265.
PMID: 34987171
DOI: 10.1038/s41580-021-00436-9.
Modeling human neurodevelopmental diseases with brain organoids.
Lu X, Yang J, Xiang Y
Cell Regen. 2022; 11(1):1.
PMID: 34982276
PMC: 8727646.
DOI: 10.1186/s13619-021-00103-6.
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome.
Stensen W, Rothweiler U, Engh R, Stasko M, Bederman I, Costa A
Pharmaceuticals (Basel). 2021; 14(11).
PMID: 34832952
PMC: 8617627.
DOI: 10.3390/ph14111170.
DYRK1A Overexpression in Mice Downregulates the Gonadotropic Axis and Disturbs Early Stages of Spermatogenesis.
Dard R, Moreau M, Parizot E, Ghieh F, Brehier L, Kassis N
Genes (Basel). 2021; 12(11).
PMID: 34828406
PMC: 8621272.
DOI: 10.3390/genes12111800.
Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.
Brault V, Nguyen T, Flores-Gutierrez J, Iacono G, Birling M, Lalanne V
PLoS Genet. 2021; 17(9):e1009777.
PMID: 34587162
PMC: 8480849.
DOI: 10.1371/journal.pgen.1009777.